AC-340

• Description :

  AC-340 is a potent hybrid VDR agonist/HDAC inhibitor. AC-340 superinduces VDR target genes (e.g., CYP24A1) and inhibits HDAC6 (IC50 = 0.37 μM) with ~10-fold selectivity over HDAC2. AC-340 induces VDR hyperagonism by causing widespread protein hyperacetylation (e.g., tubulin and H3K9/K27), which leads to elevated H3K27 acetylation on VDR target genes. AC-340 can be used for melanoma cancer research[1].

• UNSPSC :

  12352005

• Target :

  HDAC; Microtubule/Tubulin; VD/VDR

• Related Pathways :

  Cell Cycle/DNA Damage; Cytoskeleton; Epigenetics; Vitamin D Related/Nuclear Receptor

• Applications :

  COVID-19-anti-virus

• Field of Research :

  Cancer; Inflammation/Immunology

• Smiles :

  CCC(CC)(C1=CC=C(C=C1)OCCCC(NO)=O)C2=NC(C)=C(S2)CCC(C(C)(C)C)O

• Molecular Formula :

  C26H40N2O4S

• Molecular Weight :

  476.67

• References & Citations :

  [1]Sarmadi F, et al. Hyperagonism of a Vitamin D Receptor Agonist/Histone Deacetylase Inhibitor Hybrid Molecule. J Med Chem. 2025 Oct 9;68 (19) :20675-20688.

• Shipping Conditions :

  Room temperature

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• Isoform :

  HDAC2; HDAC6